The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
Clinical trial NCT06652555 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06652555
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-10-30
- Primary completion
- 2026-09-29
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.